

139. A method for hormone replacement therapy comprising orally administering to a woman;
a daily dose of 1 to 3 mg of an estrogen, and
a daily dose of 0.25 to 10.0 mg of drospirenone, wherein the drospirenone is in a form
having a surface area of more than 10 000 cm³/g.

140. A method for hormone replacement therapy comprising orally administering to a woman;
a daily dose of 1 to 3 mg of an estrogen, and
a daily dose of 0.25 to 10.0 mg of drospirenone, wherein the drospirenone is in a form
having a rapid dissolution such that at least 70% of said drospirenone is dissolved from a tablet
containing 3 mg of drospirenone in 900 ml of water at 37°C within 30 minutes, as determined by
USP XXIII Paddle Method using a USP dissolution test apparatus 2 and 50 rpm as the stirring
rate.

91
Cont (141. A method of treating a disease, disorder or symptom associated with deficient
endogenous levels of estrogen in women comprising orally administering to a woman having a
deficient endogenous level of estrogen;
an estrogen in a sufficient amount to alleviate said disease, disorder or symptom,
and micronized drospirenone in a sufficient amount to protect the endometrium from
adverse effects of estrogen.

142. A method according to claim 138, 139, 140 or 141, wherein the method is for treatment
of deficient levels of estrogen caused by natural menopause, peri-menopause, post-menopause,
hypogonadism, castration or primary ovarian failure.

143. A method according to claim 138, 139, 140 or 141, wherein the estrogen is selected from
the group consisting of estradiol, estradiol sulfamates, estradiol valerate, estradiol benzoate,
ethinyl estradiol, estrone, estrone sulfate, estriol, estriol succinate, conjugated estrogens and

mixtures thereof.

144. A method according to claim 138, 139, 140 or 141, wherein the estrogen is in micronized form.

145. A method according to claim 138, 139, 140 or 141, wherein the amount of drospirenone corresponds to a daily dose of 1 to 3.5 mg.

146. A method according to claim 138, 139, 140 or 141, wherein the estrogen and drospirenone are administered continuously.

147. A method according to claim 138, 139, 140 or 141, wherein the estrogen is administered continuously and drospirenone is administered sequentially.

148. A method according to claim 147, wherein the estrogen dosage is lower for the first 1 to 7 days immediately after finalizing said sequential administration of drospirenone.

149. A method according to claim 138, 139, 140 or 141, wherein estrogen is administered continuously and drospirenone is administered in an interrupted manner.

150. A method according to claim 138, 139, 140 or 141, wherein estrogen is administered continuously for 21 to 30 days and drospirenone is administered in a 3-day-on-3-day-off cycle.

151. A method according to claim 138, 139, 140 or 141, wherein the estrogen is ethinyl estradiol.

152. A method according to claim 140, wherein at least 80% of said drospirenone is dissolved

PS
cond, within 20 minutes by the stated test.
